Developments and challenges for new and emergent preparations for male hypogonadism treatment

References

• Naamneh Elzenaty R, du Toit T, Flück CE. Basics of androgen synthesis and action. Best Pract Res Clin Endocrinol Metab. 2022 Jul;36(4):101665. doi: 10.1016/j.beem.2022.101665
   PubMed Web of Science ®Google Scholar
• Tajar A, Forti G, O’Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male Ageing study. J Clin Endocrinol Metab. 2010 Apr;95(4):1810–1818. doi: 10.1210/jc.2009-1796
   PubMed Web of Science ®Google Scholar
• Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018 May 1;103(5):1715–1744. doi: 10.1210/jc.2018-00229
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of testosterone deficiency in men. Aging Male. 2021 Dec;24(1):119–138. doi: 10.1080/13685538.2021.1962840
   PubMed Web of Science ®Google Scholar
• Salonia A, Bettocchi C, Boeri L, et al. EAU Working Group on Male Sexual and Reproductive Health. European Association of Urology Guidelines on Sexual and Reproductive Health-2021 Update: male sexual dysfunction. Eur Urol. 2021 Sep;80(3):333–357. doi: 10.1016/j.eururo.2021.06.007
   PubMed Web of Science ®Google Scholar
• Yeap BB, Grossmann M, McLachlan RI, et al. Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy. Med J Aust. 2016 Aug 15;205(4):173–178. doi: 10.5694/mja16.00393
   PubMed Web of Science ®Google Scholar
• Morales A, Bebb RA, Manjoo P, et al. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline. CMAJ. 2015 Dec 8;187(18):1369–1377. doi: 10.1503/cmaj.150033
   PubMed Web of Science ®Google Scholar
• Khera M, Adaikan G, Buvat J, et al. Diagnosis and treatment of testosterone deficiency: recommendations from the fourth international consultation for sexual medicine (ICSM 2015). J Sex Med. 2016 Dec;13(12):1787–1804. doi: 10.1016/j.jsxm.2016.10.009
   PubMed Web of Science ®Google Scholar
• Isidori AM, Aversa A, Calogero A, et al. Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and sexual medicine (SIAMS) and the Italian Society of Endocrinology (SIE). J Endocrinol Invest. 2022 Dec;45(12):2385–2403. doi: 10.1007/s40618-022-01859-7
   PubMed Web of Science ®Google Scholar
• Corona G, Torres LO, Maggi M. Testosterone therapy: what we have learned from trials. J Sex Med. 2020 Mar;17(3):447–460. doi: 10.1016/j.jsxm.2019.11.270
   PubMed Web of Science ®Google Scholar
• Corona G, Goulis DG, Huhtaniemi I, et al. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: endorsing organization. Eur Society Endocrinol Andrology. 2020 Sep;8(5):970–987. doi: 10.1111/andr.12770
   Google Scholar
• Corona G, Cucinotta D, Di Lorenzo G, et al. Congenital adrenal hyperplasia, disorders of sex development, and infertility in patients with POR gene pathogenic variants: a systematic review of the literature. J Endocrinol Invest. 2023 Jan 25;46(1):1–34. doi: 10.1007/s40618-022-01849-9
   PubMed Web of Science ®Google Scholar
• Giagulli VA, Castellana M, Lisco G, et al. Critical evaluation of different available guidelines for late-onset hypogonadism. Andrology. 2020 Nov;8(6):1628–1641. doi: 10.1111/andr.12850
   PubMed Web of Science ®Google Scholar
• Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. [2010 Jul 8];363(2):123–135. doi: 10.1056/NEJMoa0911101
   PubMed Web of Science ®Google Scholar
• Handelsman DJ. Androgen Misuse and Abuse. Endocr Rev. 2021 Jul 16;42(4):457–501. doi: 10.1210/endrev/bnab001
   PubMed Web of Science ®Google Scholar
• Nieschlag E. Late-onset hypogonadism: a concept comes of age. Andrology. 2020 Nov;8(6):1506–1511. doi: 10.1111/andr.12719
   PubMed Web of Science ®Google Scholar
• Corona G, Vignozzi L, Sforza A, et al. Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health. 2013 Aug;31(2):103–125. doi: 10.5534/wjmh.2013.31.2.103
   PubMedGoogle Scholar
• Rastrelli G, Vignozzi L, Corona G, et al. Pharmacotherapy of male hypogonadism. Curr Opin Pharmacol. 2023 Feb;68:102323.
   PubMed Web of Science ®Google Scholar
• Corona G, Vena W, Pizzocaro A, et al. Testosterone therapy in diabetes and pre-diabetes. Andrology. 2023 Feb;11(2):204–214. doi: 10.1111/andr.13367
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Vignozzi L, et al. The role of testosterone treatment in patients with metabolic disorders. Expert Rev Clin Pharmacol. 2021 Sep;14(9):1091–1103. doi: 10.1080/17512433.2021.1938548
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Morelli A, et al. Treatment of functional hypogonadism Besides pharmacological substitution. World J Mens Health. 2020 Jul;38(3):256–270. doi: 10.5534/wjmh.190061
   PubMedGoogle Scholar
• Corona GG, Rastrelli G, Maseroli E, et al. Testosterone replacement therapy and cardiovascular risk: a review. World J Mens Health. 2015 Dec;33(3):130–142. doi: 10.5534/wjmh.2015.33.3.130
   PubMedGoogle Scholar
• Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. [2023 Jul 13];389(2):107–117. doi: 10.1056/NEJMoa2215025
   PubMed Web of Science ®Google Scholar
• Wittert GA, Grossmann M, Yeap BB, et al. Testosterone and type 2 diabetes prevention: translational lessons from the T4DM study. J Endocrinol. 2023 Sep 1;258(3). doi: 10.1530/JOE-22-0223
   PubMed Web of Science ®Google Scholar
• Green DJ, Chasland LC, Naylor LH, et al. New horizons: testosterone or exercise for cardiometabolic health in older men. J Clin Endocrinol Metab. 2023 Aug 18;108(9):2141–2153. doi: 10.1210/clinem/dgad175
   PubMed Web of Science ®Google Scholar
• Handelsman DJ. Testosterone, spermatogenesis, and unravelling the mysteries of puberty. Endocrinology. 2020 Sep 1;161(9). doi: 10.1210/endocr/bqaa120
   Web of Science ®Google Scholar
• Walker WH. Molecular mechanisms of testosterone action in spermatogenesis. Steroids. 2009 Jul;74(7):602–607. doi: 10.1016/j.steroids.2008.11.017
   PubMed Web of Science ®Google Scholar
• Thirumalai A, Amory JK. Emerging approaches to male contraception. Fertil Steril. 2021 Jun;115(6):1369–1376. doi: 10.1016/j.fertnstert.2021.03.047
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Maggi M, Corona G. What are the pharmacological considerations for male congenital hypogonadotropic hypogonadism? Expert Opin Pharmacother. 2022 Jun;23(9):1009–1013. doi: 10.1080/14656566.2022.2084690
   PubMed Web of Science ®Google Scholar
• Tharakan T, Corona G, Foran D, et al. Does hormonal therapy improve sperm retrieval rates in men with non-obstructive azoospermia: a systematic review and meta-analysis. Hum Reprod Update. 2022 Aug 25;28(5):609–628. doi: 10.1093/humupd/dmac016
   PubMed Web of Science ®Google Scholar
• Caroppo E, Colpi GM. Hormonal treatment of men with Nonobstructive Azoospermia: what does the evidence suggest? J Clin Med. 2021 Jan 20;10(3):387. doi: 10.3390/jcm10030387
   PubMed Web of Science ®Google Scholar
• Pook CJ, Cocca A, Grandone A, et al. The Evidence for Fertility Preservation in Pediatric Klinefelter Syndrome. Front Reprod Health. 2021;3:629179. doi: 10.3389/frph.2021.629179
   PubMedGoogle Scholar
• Gronski MA, Grober ED, Gottesman IS, et al. Efficacy of Nasal Testosterone Gel (Natesto(®)) Stratified by Baseline Endogenous Testosterone Levels. J Endocr Soc. 2019 Sep 1;3(9):1652–1662. doi: 10.1210/js.2019-00183
   PubMed Web of Science ®Google Scholar
• Rogol AD, Tkachenko N, Bryson N. Natesto™, a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men. Andrology. 2016 Jan;4(1):46–54. doi: 10.1111/andr.12137
   PubMed Web of Science ®Google Scholar
• Winters SJ, Takahashi J, Troen P. Secretion of testosterone and its Δ4 precursor steroids into spermatic vein blood in men with varicocele-associated infertility. J Clin Endocrinol Metab. 1999 Mar;84(3):997–1001. doi: 10.1210/jc.84.3.997
   PubMed Web of Science ®Google Scholar
• Diaz P, Reddy R, Blachman-Braun R, et al. Comparison of intratesticular testosterone between men receiving nasal, intramuscular, and subcutaneous pellet testosterone therapy: evaluation of data from two single-center randomized clinical trials. World J Mens Health. 2023 Apr;41(2):390–395. doi: 10.5534/wjmh.210261
   PubMedGoogle Scholar
• Ramasamy R, Masterson TA, Best JC, et al. Effect of Natesto on reproductive hormones, semen parameters and hypogonadal symptoms: a single center, open label, single arm trial. J Urol. 2020 Sep;204(3):557–563. doi: 10.1097/JU.0000000000001078
   PubMed Web of Science ®Google Scholar
• Mirand EA, Gordon AS, Wenig J. Mechanism of testosterone action in erythropoiesis. Nature. 1965 Apr 17;206(981):270–272. doi: 10.1038/206270a0
   PubMedGoogle Scholar
• Bachman E, Travison TG, Basaria S, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. J Gerontol A Biol Sci Med Sci. 2014 Jun;69(6):725–735. doi: 10.1093/gerona/glt154
   PubMed Web of Science ®Google Scholar
• Coviello AD, Kaplan B, Lakshman KM, et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008 Mar;93(3):914–919. doi: 10.1210/jc.2007-1692
   PubMed Web of Science ®Google Scholar
• Bachman E, Feng R, Travison T, et al. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. J Clin Endocrinol Metab. 2010 Oct;95(10):4743–4747. doi: 10.1210/jc.2010-0864
   PubMed Web of Science ®Google Scholar
• Mithoowani S, Laureano M, Crowther MA, et al. Investigation and management of erythrocytosis. CMAJ. 2020 Aug 10;192(32):E913–e918. doi: 10.1503/cmaj.191587
   PubMed Web of Science ®Google Scholar
• Ory J, Diaz P, Rivero MJ, et al. Comparing rates of polycythemia in hypogonadal men using nasal testosterone gel versus intramuscular testosterone: update of a randomized clinical trial. Eur Urol Focus. 2023 Jan;9(1):14–16. doi: 10.1016/j.euf.2022.09.001
   PubMedGoogle Scholar
• Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis following testosterone therapy. Sex Med Rev. 2018 Jan;6(1):77–85. doi: 10.1016/j.sxmr.2017.04.001
   PubMed Web of Science ®Google Scholar
• Madsen MC, van Dijk D, Wiepjes CM, et al. Erythrocytosis in a large cohort of trans men using testosterone: a long-term follow-up study on prevalence, determinants, and exposure years. J Clin Endocrinol Metab. 2021 May 13;106(6):1710–1717. doi: 10.1210/clinem/dgab089
   PubMed Web of Science ®Google Scholar
• Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010 Jun;95(6):2560–2575. doi: 10.1210/jc.2009-2575
   PubMed Web of Science ®Google Scholar
• Nackeeran S, Kohn T, Gonzalez D, et al. The effect of route of testosterone on changes in hematocrit: a systematic review and Bayesian network meta-analysis of randomized trials. J Urol. 2022 Jan;207(1):44–51. doi: 10.1097/JU.0000000000002188
   PubMedGoogle Scholar
• Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021 Jan;9(1):32–45. doi: 10.1016/S2213-8587(20)30367-3
   PubMed Web of Science ®Google Scholar
• Jones SD Jr., Dukovac T, Sangkum P, et al. Erythrocytosis and polycythemia secondary to testosterone replacement therapy in the aging male. Sex Med Rev. 2015 Apr;3(2):101–112. doi: 10.1002/smrj.43
   PubMedGoogle Scholar
• Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999 Oct;84(10):3469–3478. doi: 10.1210/jcem.84.10.6078
   PubMed Web of Science ®Google Scholar
• Date T, Paul K, Singh N, et al. Drug-Lipid Conjugates for Enhanced Oral Drug Delivery. AAPS Pharm Sci Tech. 2019 Jan 4;20(2):41. doi: 10.1208/s12249-018-1272-0
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lu Y, Qi J, et al. An update on oral drug delivery via intestinal lymphatic transport. Acta Pharm Sin B. 2021 Aug;11(8):2449–2468. doi: 10.1016/j.apsb.2020.12.022
   PubMed Web of Science ®Google Scholar
• Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004 Feb 26;2(1):12. doi: 10.1186/1477-7525-2-12
   PubMedGoogle Scholar
• Farthing MJ, Vinson GP, Edwards CR, et al. Testosterone metabolism by the rat gastrointestinal tract, in vitro and in vivo. Gut. 1982 Mar;23(3):226–234. doi: 10.1136/gut.23.3.226
   PubMed Web of Science ®Google Scholar
• Westaby D, Ogle SJ, Paradinas FJ, et al. Liver damage from long-term methyltestosterone. Lancet. 1977 Aug 6;2(8032):262–263. doi: 10.1016/S0140-6736(77)90949-7
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Mauss J, Coert A, et al. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol (Copenh). 1975 Jun;79(2):366–374. doi: 10.1530/acta.0.0790366
   PubMedGoogle Scholar
• Köhn FM, Schill WB. A new oral testosterone undecanoate formulation. World J Urol. 2003 Nov;21(5):311–315. doi: 10.1007/s00345-003-0372-x
   PubMed Web of Science ®Google Scholar
• Schnabel PG, Bagchus W, Lass H, et al. The effect of food composition on serum testosterone levels after oral administration of Andriol® Testocaps®. Clin Endocrinol (Oxf). 2007 Apr;66(4):579–585. doi: 10.1111/j.1365-2265.2007.02781.x
   PubMed Web of Science ®Google Scholar
• Newell-Price J, Huatan H, Quirke J, et al. An oral lipidic native testosterone formulation that is absorbed independent of food. Eur J Endocrinol. 2021 Oct 5;185(5):607–615. doi: 10.1530/EJE-21-0606
   PubMed Web of Science ®Google Scholar
• Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004 Apr;58(3):173–182. doi: 10.1016/j.biopha.2004.02.001
   PubMed Web of Science ®Google Scholar
• Bhat SZ, Dobs AS. Testosterone replacement therapy: a narrative review with a Focus on new oral formulations. touchRev Endocrinol. 2022 Nov;18(2):133–140. doi: 10.17925/EE.2022.18.2.133
   PubMedGoogle Scholar
• Patel M, Muthigi A, Ramasamy RJ. JATENZO®: challenges in the development of oral testosterone. Int J Impot Res. 2022 Nov;34(7):721–724. doi: 10.1038/s41443-021-00461-4
   PubMed Web of Science ®Google Scholar
• Swerdloff RS, Dudley RE. A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men. Ther Adv Urol. 2020 Jan;12:1756287220937232. doi: 10.1177/1756287220937232
   Web of Science ®Google Scholar
• Miller JA, Nguyen TT, Loeb C, et al. Oral testosterone therapy: past, present, and future. Sex Med Rev. 2023 Apr 3;11(2):124–138. doi: 10.1093/sxmrev/qead003
   PubMed Web of Science ®Google Scholar
• Asghar AA, Hashmi MR, Ahmed R, et al. Kyzatrex - oral testosterone replacement therapy. Ann Med Surg. 2022 Oct;82:104625.
   PubMed Web of Science ®Google Scholar
• White WB, Bernstein JS, Rittmaster R, et al. Effects of the oral testosterone undecanoate Kyzatrex™ on ambulatory blood pressure in hypogonadal men. J Clin Hypertens (Greenwich). 2021 Jul;23(7):1420–1430. doi: 10.1111/jch.14297
   PubMed Web of Science ®Google Scholar
• Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest. 2016 Sep;39(9):967–981. doi: 10.1007/s40618-016-0480-2
   PubMed Web of Science ®Google Scholar
• Corona G, Giagulli VA, Maseroli E, et al. THERAPY of ENDOCRINE DISEASE: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016 Mar;174(3):R99–116. doi: 10.1530/EJE-15-0262
   PubMed Web of Science ®Google Scholar
• Hudson J, Cruickshank M, Quinton R, et al. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. Lancet Healthy Longev. 2022 Jun;3(6):e381–e393. doi: 10.1016/S2666-7568(22)00096-4
   PubMedGoogle Scholar
• Reddy R, Rivero MJ, Patel M, et al. Patient Satisfaction After Switching to Jatenzo (Oral Testosterone Undecanoate): Update on an Open-label, Single-arm Clinical Trial. Eur Urol Focus. 2023 Jan;9(1):17–19. doi: 10.1016/j.euf.2022.08.005
   PubMedGoogle Scholar
• Corona G, Baldi E, Maggi M. Androgen regulation of prostate cancer: where are we now? J Endocrinol Invest. 2011 Mar;34(3):232–243. doi: 10.1007/BF03347072
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Corona G, Vignozzi L, et al. Serum PSA as a predictor of testosterone deficiency. J Sex Med. 2013 Oct;10(10):2518–2528. doi: 10.1111/jsm.12266
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Bhasin S, Cunningham GR, et al. Lessons from the testosterone trials. Endocr Rev. [2018 Jun 1];39(3):369–386. doi: 10.1210/er.2017-00234
   PubMed Web of Science ®Google Scholar
• Zeng B, Qiu S, Xiong X, et al. The effect of different administrations of testosterone therapy on adverse prostate events: a bayesian network meta-analysis. Front Endocrinol. 2022;13:1009900. doi: 10.3389/fendo.2022.1009900
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Cipriani S, Lotti F, et al. Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial. J Endocrinol Invest. 2022 Jul;45(7):1413–1425. doi: 10.1007/s40618-022-01776-9
   PubMed Web of Science ®Google Scholar
• Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005 Mar;90(3):1502–1510. doi: 10.1210/jc.2004-1933
   PubMed Web of Science ®Google Scholar
• Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004 Feb;89(2):503–510. doi: 10.1210/jc.2003-031110
   PubMed Web of Science ®Google Scholar
• Corona G, Tirabassi G, Santi D, et al. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology. 2017 Jul;5(4):671–678. doi: 10.1111/andr.12353
   PubMed Web of Science ®Google Scholar
• Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014 Jun;11(6):1554–1566. doi: 10.1111/jsm.12525
   PubMed Web of Science ®Google Scholar
• Crescioli C, Ferruzzi P, Caporali A, et al. Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog. Endocrinology. 2003 Jul;144(7):3046–3057. doi: 10.1210/en.2002-0210
   PubMed Web of Science ®Google Scholar
• Colli E, Rigatti P, Montorsi F, et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol. 2006 Jan;49(1):82–86. doi: 10.1016/j.eururo.2005.08.014
   PubMed Web of Science ®Google Scholar
• Pan MM, Kovac JR. Beyond testosterone cypionate: evidence behind the use of nandrolone in male health and wellness. Transl Androl Urol. 2016 Apr;5(2):213–219. doi: 10.21037/tau.2016.03.03
   PubMed Web of Science ®Google Scholar
• Cristina RT, Hanganu F, Dumitrescu E, et al. The impact of exogenic testosterone and nortestosterone-decanoate toxicological evaluation using a rat model. PLoS One. 2014;9(10):e109219. doi: 10.1371/journal.pone.0109219
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Kumar N, Sitruk-Ware R. 7α-methyl-19-nortestosterone (MENTR): the population council’s contribution to research on male contraception and treatment of hypogonadism. Contraception. 2013 Mar;87(3):288–295. doi: 10.1016/j.contraception.2012.08.036
   PubMed Web of Science ®Google Scholar
• Christiansen AR, Lipshultz LI, Hotaling JM, et al. Selective androgen receptor modulators: the future of androgen therapy? Transl Androl Urol. 2020 Mar;9(Suppl 2):S135–s148. doi: 10.21037/tau.2019.11.02
   PubMedGoogle Scholar
• Pencina KM, Burnett AL, Storer TW, et al. A Selective Androgen Receptor Modulator (OPK-88004) in Prostate Cancer Survivors: A Randomized Trial. J Clin Endocrinol Metab. 2021 Jul 13;106(8):2171–2186. doi: 10.1210/clinem/dgab361
   PubMed Web of Science ®Google Scholar
• Solomon ZJ, Mirabal JR, Mazur DJ, et al. Selective androgen receptor modulators: Current knowledge and clinical applications. Sex Med Rev. 2019 Jan;7(1):84–94. doi: 10.1016/j.sxmr.2018.09.006
   PubMed Web of Science ®Google Scholar
• Finkelstein JS, Yu EW, Burnett-Bowie SA. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013 Dec 19;369(25):2457. doi: 10.1056/NEJMoa1206168
   PubMedGoogle Scholar
• Kang J, Chen R, Tharakan T, et al. Novel androgen therapies including selective androgen receptor modulators. Best Pract Res Clin Endocrinol Metab. 2022 Sep;36(5):101686. doi: 10.1016/j.beem.2022.101686
   PubMed Web of Science ®Google Scholar
• Yi P, Rehmel JF, Cassidy K, et al. Disposition and metabolism of LY2452473, a selective androgen receptor modulator, in humans. Drug Metab Dispos. 2012 Dec;40(12):2354–2364. doi: 10.1124/dmd.112.047613
   PubMed Web of Science ®Google Scholar
• Mohideen H, Hussain H, Dahiya DS, et al. Selective Androgen Receptor Modulators: An Emerging Liver Toxin. J Clin Transl Hepatol. 2023 Feb 28;11(1):188–196. doi: 10.14218/JCTH.2022.00207
   PubMed Web of Science ®Google Scholar
• Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab. 1983 Jun;56(6):1278–1281. doi: 10.1210/jcem-56-6-1278
   PubMed Web of Science ®Google Scholar
• Gupta SK, Lindemulder EA, Sathyan G. Modeling of circadian testosterone in healthy men and hypogonadal men. J Clin Pharmacol. 2000 Jul;40(7):731–738. doi: 10.1177/00912700022009486
   PubMed Web of Science ®Google Scholar
• Layton JB, Kim Y, Alexander GC, et al. Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009-2013. JAMA. 2017 Mar 21;317(11):1159–1166. doi: 10.1001/jama.2016.21041
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Di Pasquale G, et al. Testosterone and cardiovascular risk: meta-analysis of interventional studies. J Sex Med. 2018 Jun;15(6):820–838. doi: 10.1016/j.jsxm.2018.04.641
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication FDA cautions about using T products for low T due to aging requires labeling change to inform of possible increased risk of heart attack and stroke with use 2013 [cited 2023 Oct]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due.
   Google Scholar
• PRAC review does not confirm increase in heart problems with testosterone medicines 2014 [cited 2023 Oct]. Available from: https://www.ema.europa.eu/en/news/prac-review-does-not-confirm-increase-heart-problems-testosterone-medicines
   Google Scholar
• Handelsman DJ, Grossmann M, Yeap BB, et al. Long-term outcomes of testosterone treatment in men: a T4DM post-randomisation observational follow-up study. J Clin Endocrinol Metab. 2023 Aug 25. doi: 10.1210/clinem/dgad485
   Google Scholar
• Ide V, Vanderschueren D, Antonio L. Treatment of men with central hypogonadism: alternatives for testosterone replacement therapy. Int J Mol Sci. 2020 Dec 22;22(1):21. doi: 10.3390/ijms22010021
   PubMed Web of Science ®Google Scholar
• Tsoutsouki J, Abbara A, Dhillo W. Novel therapeutic avenues for kisspeptin. Curr Opin Pharmacol. 2022 Dec;67:102319. doi: 10.1016/j.coph.2022.102319
   PubMed Web of Science ®Google Scholar
• Millar RP, Newton CL. Current and future applications of GnRH, kisspeptin and neurokinin B analogues. Nat Rev Endocrinol. 2013 Aug;9(8):451–466. doi: 10.1038/nrendo.2013.120
   PubMed Web of Science ®Google Scholar
• Ebrahimi F, Urwyler SA, Straumann S, et al. IL-1 antagonism in men with metabolic syndrome and Low Testosterone: a randomized clinical trial. J Clin Endocrinol Metab. 2018 Sep 1;103(9):3466–3476. doi: 10.1210/jc.2018-00739
   PubMed Web of Science ®Google Scholar
• Resko JA, Eik-Nes KB. Diurnal testosterone levels in peripheral plasma of human male subjects. J Clin Endocrinol Metab. 1966 May;26(5):573–576. doi: 10.1210/jcem-26-5-573
   PubMed Web of Science ®Google Scholar